Few studies have evaluated long-term health-related quality of life (HRQL) in patients during auto-SCT. This prospective study examined HRQL in 96 eligible patients before, during and up to 3 years after auto-SCT. The aim of the study was to make a comprehensive assessment of the frequency and severity of different symptoms in patients undergoing auto-SCT. The European Organization for Treatment and Research of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) was administered 13 times. The second week during treatment was the period when patients had the lowest HRQL regarding both total quality of life and function and symptom scales. The patients recovered quickly and just two months after transplantation the baseline values were restored. Three years after transplantation most of the items in the questionnaire had stabilized, except role function and dyspnea, which had improved. There were significant differences between multiple myeloma (MM) and lymphoma patients' physical function, quality of life, fatigue and pain during week 2. At the 3-year follow-up, lymphoma patients indicated a better HRQL than MM patients. The quick recovery of patients after transplantation suggests that treatment is well tolerated; however, the supportive care could be improved at week 2, especially for the lymphoma patients.
Introduction
SCT is an established treatment for a variety of malignant diseases as well as a small proportion of non-malignant disorders.
1,2 Use of auto-SCT, in which the patient's own stem cells are used, has increased, especially for patients with multiple myeloma (MM) and lymphoma. 1 Before the stem cell infusion, different conditioning regimens consisting of high-dose chemotherapy and/or TBI are administered. Patients undergoing auto-SCT experience a wide variety of side effects related to the treatment. Pancytopenia (risk of infection and bleeding), nausea, vomiting, diarrhea, appetite loss, sore mouth and fatigue are the most common ones. 3, 4 Larsen et al. investigated symptom occurrence, intensity and distress in patients undergoing high-dose chemotherapy with SCT. They found that appetite loss, tiredness and dry mouth were the most frequently reported symptoms in terms of both intensity and distress. 5 Side effects from the transplant are known to have an impact on the patients' health-related quality of life (HRQL). 4, 6 A variety of instruments have been developed to measure HRQL and most of them include dimensions such as physical/functional status, disease symptoms, treatment side effects, psychological status and social functioning. [7] [8] [9] One of the most used HRQL instruments is EORTC QLQ-C30, developed by the European Organization for Research and Treatment for Cancer. 10 Many of the studies investigating HRQL in patients undergoing SCT have a retrospective design, which yields an insufficient understanding and knowledge of the patients' quality of life before, during and after the transplantation. 7, 8 The studies that have a prospective and longitudinal design have followups both before and during the treatment. 4, 11 or before and after the treatment. [12] [13] [14] The aim of this study was to make a comprehensive assessment of the frequency and severity of different symptoms and HRQL for patients undergoing auto-SCT before, during and up to 3 years after transplantation.
Materials and methods

Study subjects and procedure
This prospective and longitudinal study consecutively invited all adult patients (n ¼ 111) at the Department of Hematology at Linko¨ping University Hospital from November 2002 until October 2005. The patients were regularly assessed over a 3-year period and the last 3-year follow-up was performed in October 2008.
Inclusion criteria were at least 18 years of age, ability to speak and read the Swedish language, ability to give informed consent, taking part in the data collection procedure and undergoing first SCT. On arrival at the transplant unit, all subjects were invited to participate in the study. In accordance with the Declaration of Helsinki, patients received verbal and written information about the study stating that participation was voluntary and confidentiality was guaranteed. The study was approved by the Ethical Committee at Linkoping University. . Day À1 was a resting day for all patients. Stem cells were re-infused on day 0. Patients were provided with protective care in special isolation rooms with a high-efficiency air filter when the WBCs were fewer than 1.0 Â 10 9 per L and were isolated until the WBCs rose over 1.0 Â 10 9 per L, which occurred after a mean of 10 (range 3-16) days.
Treatment regimens
Data collection
Measurement of HRQL. The Swedish version of the EORTC QLQ-C30 was used to measure HRQL. The questionnaire was developed by the EORTC Study Group. It is a multidimensional, cancer-specific, and self-administered instrument, 15 cross-culturally tested for reliability and validity. 7, [15] [16] [17] The instrument consists of 30 items divided into three major domains: functional scales, global health/quality of life (QoL) scale and symptom scales. Functional scales consist of physical (five items), role (two items), emotional (four items), social (two items) and cognitive (two items) items. QoL scale consists of two items. There are nine symptom scales focusing on fatigue (three items), nausea and vomiting (two items), pain (two items), dyspnea (one item), insomnia (one item), appetite loss (one item), constipation (one item), diarrhea (one item) and financial difficulties (one item).
The functional and symptom scales comprise four levels (possible answers: not at all, a little, quite a bit and very much). Overall QoL is measured on a seven-point scale, ranging from one (very poor) to seven (excellent). All scales and items were transformed according to the EORTC scoring manual into a 0-100-point scale. 18 Higher scores for functional scales and QoL status indicated a high level of function, and higher scores on the symptom scales and single items indicated more severe symptoms or impairments. Clinical data were extracted from the patients' medical records (Table 1) .
A total of 13 questionnaires per patient were distributed at baseline (the day before the start of conditioning), once a week during weeks 1-4, once a month during months 2 and 3, once at month 6 and once every six months up to year 3 after SCT. Dates for distribution of the questionnaires were based on the date for the baseline questionnaire. After discharge from the hematology unit, questionnaires were sent to the patients together with a prepaid return envelope. The questionnaires were distributed and collected by one of the authors (UF). Nonresponders received new questionnaires as a reminder. The proportion of nonresponders was below 5%, 58 out of 1040 questionnaires required reminders and the patients replied within a week.
Statistical analysis
According to the scoring manual for EORTC QLQ-C30, missing data were classified as missing items (one or more missing answers to questions within a questionnaire) or missing forms (the whole questionnaire is missing for a patient).
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The results are presented using descriptive statistics: number, proportion, mean, and s.d. In order to explore differences in HRQL between the two largest diagnostic groups, MM and lymphoma, descriptive statistics with adjusted mean values are given at baseline, week 2, month 2 and year 3. The adjusted means have been developed using a multivariate regression model with sex and age as fixed covariates in every model. 19 Separate multiple regressions were conducted at each time and for all questions in order to obtain question-specific adjusted means over time. A P-value o0.01 was considered significant, and the low significance level was set to avoid false-positive results. All analyses were performed using SPSS 17.0.
To test if characteristics differed between patients at baseline and the respondents at 3 years of follow-up, a w 2 -test was conducted on the categorical data. P-value at 0.05 was considered significant.
Results
Study group
From November 2002 until October 2005, a total of 111 patients underwent auto-SCT at the Department of Hematology at Linko¨ping University hospital. In line with the inclusion criteria 96 of these patients were included in our study. Eight of the eligible patients did not meet the inclusion criteria (five due to a secondary transplant, one was o18 years old, two had language problems. Seven patients were not included for other reasons (one for logistical reason, three declined participation, one died and two gave no reason), which gives a study population of 96 patients ( Figure 1 ). Clinical data on the patients are shown in Table 1 . In the study group, six types of diagnosis were represented, the majority of the patients being diagnosed with MM or lymphoma. The mean age for the whole group was 54, whereas the mean ages in the MM and lymphoma groups were 60 and 47, respectively. The majority (65%) of the total study population were men. A total of 61% of the 54 patients in the MM group were men and 69% of the 32 patients in the lymphoma group were men. Disease status at transplantation was CR for 11% of the patients, 67% were in PR, 4% had a minimal response, 3% were untreated/had secondary progressive/stable disease, 7% were in relapse/showed progression and the disease status of 7% of the patients was unknown. Two patients did not 15 Auto-SCT and quality of life U Frödin et al answer the baseline questionnaire and four patients did not return the questionnaire at the 3-year follow-up. During the study period the number of patients remaining in the study group diminished over time, leaving 53 (55%) patients providing data at the 3-year follow-up (Figure 1 ). During the first 3 years 30 patients (31%) died. A total of 13 patients (14%) were excluded from the study because of a second transplant (nine patients) or loss to follow-up (four patients). The most common cause of death was relapse: 15 patients (50%) in the MM group and 8 patients (27%) in the lymphoma group. Disease status for the whole group 3 years after transplantation was CR for 43% of the patients; 34% were not in CR (that is, stable disease, PR or ongoing progression); 11% had their first relapse/progression, and the disease status of 11% of the patients was unknown. There were no significant differences in mean age (54 vs 54) or gender distribution between the patients who died and those who were alive throughout the study. Almost the same results were found in the MM and lymphoma group (data not shown). At 3 years after transplantation in the MM group, one patient was still in CR and 16 patients were not. A total of six patients just had a relapse and the disease status of five patients was not known. In all, 20 of the lymphoma patients were in CR, one patient was not and the disease status of one patient was not known (Table 1) . In all, 92% of the remaining 53 patients answered the questionnaire at year 3. Figure 2 ). With the lowest value during week 2, physical function decreased by 42%, role function by 84%, social function by 65%, emotional function by 14% and cognitive function by 26% compared with the baseline. From week 3 onward there was evidence of recovery in the functional scales and at the assessment at month 2 almost all function scales had returned to the same value as at baseline. Role function was the only scale that tended to improve at the 3-year follow-up compared with baseline (Table 2, Figure 2 ).
Functional items
Compared with the baseline, patients expressed a decline in all functional scales in weeks 1 and 2 (
Symptom items
All of the measured symptoms, with the exception of constipation, clearly deteriorated from baseline to week 2 ( Figure 3 ). Nausea and vomiting, loss of appetite, fatigue and diarrhea were the symptoms that showed the worst deterioration. As early as assessment week 3 following auto-SCT, the symptom values improved and two months after the transplant all symptom scales had returned to the baseline value. At 1, 2 and 3 years after the transplant patients reported values on the symptom scales similar to those they reported at baseline, except for fatigue and dyspnea at the 3-year assessment, which tended to be improved compared with baseline (Table 2, Figure 3 ).
Overall QoL
Patient ratings of overall QoL decreased from baseline and reached the lowest level during the second week ( Figure 4 ). Patients assessed their QoL higher at week 3, and 2 months after transplantation the ratings of overall QoL had returned to a value similar to that before transplantation. Thereafter, values for QoL remained stable in the 1-, 2-and 3-year assessments (Table 2, Figure 4 ).
Comparison between MM and lymphoma patients
Adjusted mean values for MM and lymphoma patients showed that there were no significant differences between them at baseline. During week 2 there was a significant difference in physical function (P ¼ 0.001), overall QoL (Po0.001), fatigue (P ¼ 0.009) and pain (P ¼ 0.003) between the two groups. The only significant difference 2 months after transplantation was in appetite loss where the MM group had a value of 6 compared with 22 in the lymphoma group (P ¼ 0.005). At 3 years after transplantation there was no significant difference between MM and lymphoma patients (Table 3) .
Discussion
This study provides unique data on the patients' selfestimated HRQL covering the whole transplantation period and the first 3 years thereafter. It gives an overall picture of how patients experienced their HRQL before, during and after the transplant, and how the symptoms fluctuated over time. The study also shows rare data on the difference in overall QoL and symptom patterns between the two largest diagnostic groups: patients with MM and lymphoma. We only found two studies that compared lymphoma and myeloma patients undergoing auto-SCT, and they focused on mucositis.
20,21
Patients recovered fairly quickly after transplantation; as early as the second month, nearly all values on the scales had returned to the baseline values. Role and social functions were affected more before and during the transplant than other functions. Ratings of the overall QoL followed the same pattern as the other items, returned to the baseline value at month 2 and then remained stable. The same pattern of initial deterioration and rather rapid recovery was also seen when MM and lymphoma patients were analyzed separately, although there were some significant differences between the groups at week 2. The results confirm the clinical picture of how these patients felt and perceived their situation and add to the findings from other studies in this area. 4, 5, 22 Compared with a group of patients drawn from the Swedish general population reported in a study from the year 2000, the patients in our study already had an impaired HRQL at the baseline assessment: physical function (76 vs 90), role function (45 vs 87), social function (68 vs 91), quality of life (63 vs. 76), fatigue (36 vs 21) and dyspnea (32 vs 18) . 17 The patients' experience of their role function (that is, ability to participate in work, daily activities, hobbies and leisure time) at baseline was the item that they estimated the lowest compared with the other functional items. A total of 79 patients in the Frick et al. study completed EORTC QLQ C-30 and estimated their role function before auto-SCT to be 43.16 compared with 45 in our study. 23 Almost the same result was found by the Nordic Myeloma Group studying autologous transplant patients 24 and Hjermstad and colleagues 22 who studied HRQL and fatigue 3 years or more after transplantation. Both MM and lymphoma patients in our study had a negatively influenced QoL at baseline, indicating that both groups had been affected by their disease and treatment history, which probably had consequences for the ability to live their lives as they did before they were ill. Week 2 was the period during which patients felt the most affected in terms of overall quality of life, functional status and symptom burden. This week is a critical period because the auto-SCT treatment is completed and the patients' WBCs are at their nadir, with infection and mucositis as a result. .  49  56  65  74  81  85  90  90  90  81  93  91  94   Base  y3  y2,5  y2  y1,5  y1  m6  m3  m2  w4  w3 w2 w1 The results show the importance of conducting frequent follows-ups during transplantation in order to relieve symptoms in a timely manner. The patients recovered quickly and as early as week 3 they began to experience improvement. At 2 months after transplantation all scales on the EORTC QLQ C-30 had returned to baseline values, or better, for the whole group. To the best of our knowledge, this is one of the few studies showing a rapid recovery using EORTC QLQ C-30. 6 MM patients had higher values for pain than did lymphoma patients at the baseline level, which is in accord with the general symptoms of patients with MM. 25 Even though adjustments for age and sex were made between MM and lymphoma patients, there were, during week 2, significant differences between the groups in physical function, quality of life, pain and fatigue. MM patients indicated the same pain levels as at baseline, but the lymphoma patients experienced significantly more pain compared with baseline. The pain MM patients experienced during week 2 are probably not due to the disease itself. Guldbrandsen et al. found in their study that, after starting the high-dose treatment, there was an improvement regarding pain in patients with MM. 26 Blijlevens et al. examined the incidence of oral mucositis in 109 MM patients and 88 lymphoma patients undergoing high-dose therapy with SCT. They found that regardless of the diagnosis, severe mucositis occurred in more than 40% of the patients. 20 The most probable cause of pain in this study during week 2 for both MM and lymphoma patients was mucositis. 27, 28 and the likely explanation is that the high-dose treatment in MM patients had an effect on disease-related pain. We need to become better at preventing and treating mucositis through improved cooperation with the hospital dentistry department and by developing care plans. 21, 29 The study population changed over time; 3 years after the transplantation 30 patients had died and a further 13 patients had dropped out of the study, leaving a study population of 53 patients. We found no significant differences between the patients who dropped out and those alive. Age and gender distribution is fairly equal except that the main cause of death was relapse and this was twice as common among MM patients compared with lymphoma patients (50 vs 27%). The same result was found in a population-based study by the Nordic Myeloma Study Group: 56 out of 120 patients (47%) aged 60-64 years had died as a result of disease-related factors. 30 This gave in our study, 3 years after transplantation, a study population of approximately two equal groups of MM and lymphoma patients (28 and 22) , which provides better opportunities for comparison.
A limitation of this study is the loss of participants over time, but that is unfortunately unavoidable and reflects the normal clinical picture particularly regarding patients with MM. Strength of this study is the frequent follow-ups over a long period of time and the use of a well-validated questionnaire. One of the advantages of close follow-ups is that the real turnaround point for the patients becomes visible. This means that health professionals can give the patient more realistic information about how long it will take to recover after transplantation based on the elements of the quality of life that this instrument measures.
EORTC QLQ-C-30 is a good overview tool and, as a rule, patients did not find it difficult to complete the questionnaire, although some of them indicated that it was difficult to answer the questions about physical function during the inpatient period because they had limited opportunities to carry out these activities, for example, carrying heavy bags or a suitcase, or taking a long or a short walk outside the house. One weakness of the instrument is that it does not measure items in other areas of life, which may be important to the patient. Kopp et al. compared EORTC QLQ C-30 with the Functional Assessment of Cancer Therapy BMT instrument and their conclusion was that the EORTC QLQ C-30 appears to have its main focus on measuring physical and functional aspects of the quality of life and symptoms and is therefore relevant during and immediately after transplantation. 31 Our conclusion is that the EORTCQLQ C-30 is a good tool to use especially during the first 3 months after transplantation, and another instrument could possibly be used to cover other parts of the quality of life in combination with the EORTC QLQ C-30 after the first 3 months. When the present study began, no instrument for patients undergoing high-dose chemotherapy had been translated into Swedish. Since then Hjermstad et al. 32 have developed a 19-item module, HDC-19, which focuses on physiological symptoms and psychological problems in order to add to the core questionnaire. The HCD-19 questionnaire addresses areas such as sexuality, skin and mucosal problems, concern about relapse, the future and so on. Andersson et al. 33 translated the questionnaire into Swedish and showed that the Swedish version of HDC-19 is a reliable and valid HRQOL instrument for patients receiving SCT. Hopefully, this instrument can be used together with EORTC QLQ C-30.
There are no clear recommendations concerning changes in the scores that are considered clinically relevant for EORTC QLQ C-30. Fayers and Bottomley state in their article that some scientists consider a change from 10 to 20 points to be a moderate change, and changes greater than 20 constitute a major change. Others believe that a change of about 10% is a moderate change. 34, 35 In this study, we consider differences greater than 10 points on the EORTC QLQ C-30 scale to be clinically important, 36, 37 which is clearly indicated during week 2.
The conclusion drawn from this study is that week 2 is the period in which auto-SCT patients need the most supportive care. Lymphoma patients indicated a lower HRQL during this period compared with MM patients and many therefore need extra support during this period. Patients recovered quickly after auto-SCT, suggesting that transplantation was well tolerated by the majority of the patients. However, the results on the group level in the later phase of the follow-up period may be influenced by the dropout of patients over time. The results highlight the fact that clinicians need to provide extra support during transplantation for patients and patient groups that need more supportive treatment and care than other patients, especially during the acute phase of transplantation.
